Clinical Trials
340 trialsSANGUINE
JaxBio Ltd
A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma
Wuerzburg University Hospital
TAURUS
European Myeloma Network B.V.
An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma
Changzhou No.2 People's Hospital
Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.
RenJi Hospital
A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
Pharmacosmos A/S
TEDROMM
Regina Elena Cancer Institute
Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Step down ward
Siriraj Hospital
Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
CARsgen Therapeutics Co., Ltd.
Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation
Hospital Galdakao-Usansolo
RithMM
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma
Shanghai Simnova Biotechnology Co.,Ltd.
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Duke University
LI-TASTE
Academic Centre for Dentistry in Amsterdam
Study of FasT CAR-T GC012F Injection NDMM Patients
Shanghai Changzheng Hospital
Biomechanical and Metabolic Assessment Pre and Post Vertebroplasty in Multiple Myeloma Patients With Vertebral Collapse
Centro di Riferimento Oncologico - Aviano
Preliminary Assessment of [18F]BL40 in PET/CT Scans
British Columbia Cancer Agency
SPODUMENE
Peking University People's Hospital
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
CAREMM-2305
Seoul St. Mary's Hospital
A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM
Peking University First Hospital
Efficacy and Safety Evaluation of PD1-BCMA-CART
Bioray Laboratories
Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma
Shanxi Province Cancer Hospital
CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma
Sichuan University
ATG-010(Selinexor) in Combination With Chemotherapy in RRMM
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
University of Tennessee
Study for Validation of Target Therapy in Multiple Myeloma Cells From Patients With miRNAs Released From B Cells, and Study of the Bone Marrow Tumor Microenvironment (Microenvironment of MM)
Centro di Riferimento Oncologico - Aviano
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
Hellenic Society of Hematology
A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
Keymed Biosciences Co.Ltd
Lapelga vs Gastrofil
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
Oncotherapeutics
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Ascentage Pharma Group Inc.
the Safety and Efficacy of SENL103 Autologous T Cell Injection
Hebei Senlang Biotechnology Inc., Ltd.
Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma
LanZhou University
Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma
Chongqing University Cancer Hospital
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
First Affiliated Hospital of Fujian Medical University
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
PAMM-HAD1
Assistance Publique - Hôpitaux de Paris
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab Tests
Sohag University
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
Rutgers, The State University of New Jersey
VICTORY
Melbourne Health
ITUMM
Isala
THD-MM-Reg
Turkish Hematology Association
Double Filtration Plasmapheresis Combined With Chemotherapy
Zhongnan Hospital
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
Singapore General Hospital
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
Hoag Memorial Hospital Presbyterian